The MET kinase inhibitor SU11274 has been studied in non-small cell lung cancer xenografts resulting in inhibition of tumor growth (Tang et al., 2008), but whether pharmacological administration of HGF can lead to cancer development in the absence of oncogene or tumor suppressor alterations is unclear. Here, HGF is linked to neoplasm.